STOCK TITAN

Agenus Inc - AGEN STOCK NEWS

Welcome to our dedicated news page for Agenus (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Agenus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Agenus's position in the market.

Rhea-AI Summary
Agenus Inc. will release its first quarter 2024 financial results on May 7, 2024. The company is a leader in developing novel immunological agents to treat various cancers. Agenus executives will discuss the results and provide a corporate update during a conference call and webcast at 8:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Agenus Inc. (AGEN) announces updated Phase 1 data showing a 71% 12-month overall survival rate and 62% 18-month overall survival rate for BOT/BAL combination therapy in metastatic colorectal cancer (CRC) patients. The company plans to discuss Phase 2 interim results with the FDA and submit data to a major medical conference in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1737.66%
Tags
-
Rhea-AI Summary
Agenus Inc. announces a one-for-twenty reverse stock split to enhance financing flexibility and meet listing requirements. The split will be effective on April 12, 2024, maintaining the common stock's par value at $0.01 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
Rhea-AI Summary
FDA grants Fast Track designation for BOT/BAL in metastatic, refractory colorectal cancer patients. Agenus reports 2023 financial results and significant clinical advancements in BOT/BAL development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.94%
Tags
-
Rhea-AI Summary
Agenus Inc. announces preclinical data on BMS-986442 (AGEN1777) demonstrating superior immune activation in advanced solid cancers. The novel bispecific antibody targets TIGIT and CD96, offering a promising approach to enhance anti-tumor immunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
-
Rhea-AI Summary
Agenus Inc. announced the grant of inducement awards to key executives Nils Eckardt, Kent Barnes, and Brian Greenblatt. The awards include stock options and restricted stock units, subject to service relationships and vesting conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
Rhea-AI Summary
Agenus Inc. announces the release of its fourth quarter and year-end 2023 financial results on March 14, 2024. The company, known for its novel immunological agents to treat cancers, will host a conference call and webcast to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.81%
Tags
-
Rhea-AI Summary
Agenus Inc. (AGEN) announces Dr. Garo Armen, Chairman and CEO, to participate in fireside chat and investor meetings at Leerink Global Biopharma Conference. Webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
conferences
-
Rhea-AI Summary
Ginkgo Bioworks and SaponiQx, Inc. have been awarded a 5-year, $31 million contract by DTRA's JSTO for the CBD Program to develop next-generation vaccine adjuvants. The partnership aims to discover novel saponin-based adjuvants using high-throughput empirical and AI/machine learning approaches, potentially leading to innovative vaccines against biothreat agents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.11%
Tags
none
Rhea-AI Summary
Agenus Inc. announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the Oppenheimer Healthcare Conference. The fireside chat will be live webcasted and replayed on the company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags
conferences
Agenus Inc

Nasdaq:AGEN

AGEN Rankings

AGEN Stock Data

131.96M
17.69M
1.2%
59.18%
11.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Lexington

About AGEN

agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody